Drugs / Recombinant human vascular endostatin
Recombinant human vascular endostatin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05385185 | May 2022 → May 2024 | neoplastic meningitis | Hebei Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human vascular endostatin | “combine Camrelizumab or envafolimab with Recombinant human vascular endostatin” NCT05385185 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human endostatin” NCT05385185 ↗ |
| Route | Intravenous | “Endostatin 30mg/d was administered intravenously for 7 days” NCT05385185 ↗ |